Cite
Cobimetinib Plus Vemurafenib in Patients With Colorectal Cancer With BRAF Mutations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.
MLA
Klute, Kelsey A., et al. “Cobimetinib Plus Vemurafenib in Patients With Colorectal Cancer With BRAF Mutations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.” JCO Precision Oncology, vol. 6, Nov. 2022, pp. 1–10. EBSCOhost, https://doi.org/10.1200/PO.22.00191.
APA
Klute, K. A., Rothe, M., Garrett-Mayer, E., Mangat, P. K., Nazemzadeh, R., Yost, K. J., Duvivier, H. L., Ahn, E. R., Cannon, T. L., Alese, O. B., Krauss, J. C., Thota, R., Calfa, C. J., Denlinger, C. S., O’Lone, R., Halabi, S., Grantham, G. N., & Schilsky, R. L. (2022). Cobimetinib Plus Vemurafenib in Patients With Colorectal Cancer With BRAF Mutations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. JCO Precision Oncology, 6, 1–10. https://doi.org/10.1200/PO.22.00191
Chicago
Klute, Kelsey A., Michael Rothe, Elizabeth Garrett-Mayer, Pam K. Mangat, Reza Nazemzadeh, Kathleen J. Yost, Herbert L. Duvivier, et al. 2022. “Cobimetinib Plus Vemurafenib in Patients With Colorectal Cancer With BRAF Mutations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.” JCO Precision Oncology 6 (November): 1–10. doi:10.1200/PO.22.00191.